ArticleCureus2025
Outcomes in Patients With Tumor Lysis Syndrome and Comorbid Gout: A Propensity-Matched Study From a Global Federated Health Research Network.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Tumor lysis syndrome (TLS) is an oncologic emergency that can result in cardiac arrhythmias, acute kidney injury (AKI), seizures, and death. Uric acid released in TLS can be managed with gout medications. We used a national database to study the impact of gout on patients with TLS. Methods The TriNetX US Collaborative Network was used for ICD-10 (International Classification of Diseases) code data. Adults with TLS were divided according to gout diagnosis. Uric acid-lowering therapies (ULTs), including allopurinol, febuxostat, and rasburicase, were studied. Cohorts were propensity-matched based on age, sex, race, and comorbidities. Rates of mortality, AKI, seizures, atrial fibrillation (AF), atrial flutter (AFL), Torsade de Pointes (TP), continuous renal replacement therapy (CRRT), septic arthritis, sepsis, intensive care unit (ICU) admission, and hospital admission were tracked for five years. Results TLS without gout demonstrated a higher risk of mortality (HR: 1.146; 95% CI: 1.065-1.233; p = 0.0038), AKI (HR: 1.02; 95% CI: 0.956-1.089; p = 0.0017), and sepsis (HR: 1.014; 95% CI: 0.926-1.111; p = 0.0158). TLS without allopurinol had higher risks of AKI (HR: 1.489; 95% CI: 1.337-1.658; p = 0.000), AF/AFL (HR: 1.046; 95% CI: 0.886-1.235; p = 0.002), and sepsis (HR: 1.375; 95% CI: 1.188-1.591; p = 0.027). TLS without rasburicase had a higher risk of mortality (HR: 1.165; 95% CI: 0.747-1.818; p = 0.024). Conclusion Patients with TLS have a higher risk of mortality, AKI, and sepsis than patients with TLS and gout. Gout and ULTs could be protective in TLS. Further research is warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.